In laboratory and animal studies, a 2-pronged gene therapeutic approach resulted in tumor regression and long-term survival; next step is a human clinical trial

Researchers at the Salk Institute for Biological Studies have developed a versatile mouse model of glioblastoma—the most common and deadly brain cancer in humans—that closely resembles the development and progression of human brain tumors that arise naturally.

UC Davis Cancer Center researchers report today the discovery of a molecule that targets glioblastoma, a highly deadly form of cancer. The finding, which is published in the January 2009 issue of the European Journal of Nuclear Medicine and Molecular Imaging, provides hope for effectively treating an incurable cancer.

Scientists have developed a new drug delivery system that is capable of crossing the blood-brain barrier to reach and kill cancer cells in the brain, according to research presented at the 20th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Geneva today (Wednesday 22 October).

AngioChem, Inc., a clinical-stage biotechnology company dedicated to creating and developing new drugs to treat brain diseases, announced today that its lead product, ANG1005, is safe and well tolerated in patients with brain cancer treated to date.

Major research initiatives are needed immediately to assess the possibility that using cellular phones may lead to an increased risk of brain tumors, according to an editorial in the November issue of the journal Surgical Neurology, published by Elsevier.

One of the primary ways of treating brain cancer is surgically removing the tumors. The risk of this sort of procedure is obvious -- it involves cutting away tissue from the brain, potentially severing nerve fibers and causing neurological damage.

Some scientist believe there is a connection between brain cancer and cell phones.

Scientists at The University of Nottingham have isolated three important genes involved in the development of a type of childhood brain cancer. The breakthrough is revealed in a study published in the British Journal of Cancer.

The Cancer Genome Atlas (TCGA) Research Network, a collaborative effort funded by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), today reported the first results of its large-scale, comprehensive study of the most common form of brain cancer, glioblastoma (GBM).

Researchers at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center recently participated in a pilot study with the Montreal Neurological Institute that suggests a certain type of MRI scanning can detect when a patient is failing brain tumor treatment before symptoms appear.

Individuals with glioblastoma multiforme (GBM), one of the most aggressive types of brain tumor, have an extremely poor prognosis.